ArticleReviews in urology2010
A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.
Article in Reviews in urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome.International journal of environmental research and public health · 2021Article
- Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- MetabolicMolecules (Basel, Switzerland) · 2021Review
- Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.Neurourology and urodynamics · 2020Article
- Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.The AAPS journal · 2017Article
- Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013.Clinical pediatrics · 2017Article
- Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.Drugs & aging · 2015Review
- Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.Research and reports in urology · 2013Review
- Oxybutynin: past, present, and future.International urogynecology journal · 2013Review
- Management of urinary incontinence.P & T : a peer-reviewed journal for formulary management · 2012Article
- Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder.Research and reports in urology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimuscarinic agents remain the mainstay of treatment of overactive bladder. However, the utility of some of these agents is limited due to tolerability concerns, multiple daily dosage regimens, lack of formulary coverage, and high cost. This can lead to problems with long-term compliance and may preclude optimal management. Oxybutynin has been the most widely prescribed antimuscarinic agent for more than 30 years. To meet the needs of tolerability and compliance, oxybutynin has evolved from an immediate-release pill to a once-daily oral dose and is now available as a topical gel. This review compares the various oxybutynin formulations in terms of pharmacokinetics, efficacy, and tolerability issues.
Indexed as
Identifiers
20428289PMC2859137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.